News

HUTCHMED Receives Breakthrough Therapy Designation from China’s NMPA

September 14, 2021

HUTCHMED’s amdizalisib (HMPL-689) received breakthrough therapy designation for the treatment of a subtype of non-Hodgkin’s lymphoma.

Former FDA Scientists Dispute Need for Booster Vaccines

September 14, 2021

Both Marion Gruber and Phillip Krause, FDA officials, co-authored a document disputing the need for COVID-19 boosters for most people.

ABITEC Enters into Memorandum of Understanding with Luca AICell

September 13, 2021

The memorandum of understanding between ABITEC and Luca AICell will work to advance ultra-high purity lipidic chemistries.

Boehringer Ingelheim and Twist Bioscience Team Up for Therapeutic Antibody Discovery

September 13, 2021

Boehringer Ingelheim and Twist Bioscience will use Twist’s antibody libraries to discover therapeutic antibody candidates.

FDA Approves Janssen’s Invega Hayfera for Schizophrenia Treatment

September 10, 2021

Janssen’s Invega Hayfera is the first six-month injectable schizophrenia treatment approved by FDA.

Vector Laboratories Closes $124 Million Buyout

September 10, 2021

Vector Laboratories has completed a $124 million cash buyout backed by Thompson Street Capital Partners and will begin an acquisition strategy to expand protein detection capabilities.

Eight Patient Leaders Join ABPI Advisory Council

September 10, 2021

ABPI has announced that eight leaders from the patient and health charity sector have been chosen to join its new Patient Advisory Council.

ILC Therapeutics Successfully Closes Pre-IPO Funding Round

September 10, 2021

ILC Therapeutics, has successfully closed a £3.5 million (US$4.9 million) pre-initial public offering (IPO) funding round.

Janssen’s Erleada is Reconsidered by NICE, Gaining a Positive Recommendation

September 10, 2021

NICE has reconsidered its decision on Janssen's Erleada (apalutamide), issuing two positive final appraisal determinations (FADs) on the therapy.

NICE Issues Recommendation for Pfizer’s Juvenile Idiopathic Arthritis Treatment

September 10, 2021

NICE has recommended tofacitinib (Xeljanz, Pfizer)as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis.